Humacyte (HUMA) Stock Statistics & Valuation Metrics

Humacyte has a market cap or net worth of $223.30M. The enterprise value is $370.50M.

Humacyte has 158,372,180 shares outstanding. The number of shares has decreased by -2.65% in one year.

Humacyte’s return on equity (ROE) is 2.82 and return on invested capital (ROIC) is -94.67%.

The current PE Ratio of Humacyte is ―. Humacyte’s PEG ratio is ―.

In the last 12 months, Humacyte had revenue of 0.00 and earned -148.70M in profits. Earnings per share was -1.26.

In the last 12 months, operating cash flow was -104.50M and capital expenditures -1.79M, giving a free cash flow of -106.29M billion.

Humacyte pays an annual dividend of ―, resulting in a dividend yield of ―

Humacyte upcoming earnings date is Nov 7, 2025, Before Open (Confirmed).

Humacyte as a current ratio of 2.40, with Debt / Equity ratio of 373.22%

In the past 12 months, Humacyte has paid 0.00 in taxes.

Humacyte EV to EBITDA ratio is -4.31, with an EV/FCF ratio of -5.72.

Humacyte has $38.03M in cash and marketable securities with $15.12M in debt, giving a net cash position of -$22.91M billion.

Gross margin is 5.32%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Humacyte is $5.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy